Healthleap Raises $38M for AI Identifying At-Risk Hospital Patients

Healthleap, a South African-born digital health startup, has secured $38 million in combined seed and Series A funding to accelerate development of its artificial intelligence platform designed to identify hospitalized patients at risk of undiagnosed or overlooked conditions. The financing consists of an $8 million seed round co-led by Sequoia Capital and First Round Capital, alongside a $30 million Series A led by Hummingbird Ventures. Co-founders and siblings Jemima and Josiah Meyer will allocate the capital toward engineering, commercial expansion, and product scaling. Originally launched in 2022 as a clinical nutrition tool, Healthleap pivoted to address broader hospital-acquired risks. The platform integrates directly into electronic health record systems, deploying language models to parse unstructured clinician notes alongside structured data such as laboratory results, vital signs, and medication histories. By extracting clinical indicators like recent weight loss, appetite deterioration, or muscle atrophy, the system generates daily risk assessments that integrate seamlessly into existing clinical workflows. The software functions as a surveillance tool rather than a diagnostic system, prompting care teams to investigate conditions including malnutrition, delirium, aspiration pneumonia, pressure ulcers, and heart failure readmission risks. Commercial adoption has accelerated rapidly, with deployments now spanning more than fifty facilities across major US health networks, including Penn Medicine, Cedars-Sinai, Intermountain Healthcare, Houston Methodist, and Emory Healthcare. Revenue has grown tenfold over the past year under a three-year contracting model priced according to licensed bed capacity. The company supplements this with an outcome-based pricing structure, claiming deployed systems generate between five and twenty times annual return on investment for participating hospitals. Reported financial impacts stem primarily from reduced length of stay and optimized reimbursement capture, with early deployments demonstrating tens of millions in annualized savings. Healthleap plans to utilize the fresh capital to broaden its clinical scope to more than forty major health conditions and extend monitoring capabilities into outpatient and home care environments. The expansion will be supported by enhanced engineering, sales, and customer success teams. As healthcare systems continue navigating diagnostic latency and staffing pressures, the startup’s AI-driven patient screening approach presents a scalable mechanism for early clinical intervention, improved resource allocation, and measurable financial performance.